Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, has announced that John Houston and Ian Taylor will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 10:00 a.m. ET. The event will be available via a live audio webcast and archived for 30 days on Arvinas' website. Arvinas aims to improve patient lives by developing therapies that degrade disease-causing proteins, with two clinical-stage programs: ARV-110 for prostate cancer and ARV-471 for breast cancer.
Arvinas, Inc. (Nasdaq: ARVN) announced plans to lease approximately 160,000 square feet at 101 College Street in New Haven, Connecticut. This move will facilitate the company’s continued growth in the biopharmaceutical sector, particularly in its efforts to develop targeted protein degradation therapies. The new facility is expected to be complete and ready for occupancy by 2024. This decision is seen as a testament to Arvinas' commitment to the local economy and its ongoing partnership with Yale University.
Arvinas, Inc. (Nasdaq: ARVN) reported its Q1 2021 financial results, revealing a net loss of $41 million, up from $21.7 million in Q1 2020. Revenues decreased to $5.5 million from $6.2 million, impacted by a collaborator's extended revenue recognition period. R&D expenses rose to $34.9 million, primarily due to ongoing platform investments. Arvinas maintains a strong cash position of $651.3 million, expected to fund operations into 2024. Key milestones include anticipated data presentations for ARV-110 and ARV-471 in 2021, reinforcing its leadership in targeted protein degradation.
On April 5, 2021, Arvinas, a clinical-stage biotechnology company, announced two presentations at the AACR Annual Meeting 2021, focusing on its PROTAC degraders, ARV-110 and ARV-471. These presentations will be held virtually from April 10-15, 2021, and May 17-21, 2021.
ARV-110 targets metastatic castration-resistant prostate cancer, while ARV-471 is aimed at ER+/HER2- breast cancer. Both presentations are scheduled for April 11, 2021, delivered by Dr. Lawrence B. Snyder. Abstracts will be available on the AACR website starting April 9, 2021.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two virtual investor conferences. Dr. John Houston, President and CEO, will speak at the Guggenheim Targeted Protein Degradation Day on March 16, 2021, and at the 33rd Annual Roth Conference on March 17, 2021. Both panel discussions will be accessible via live audio webcasts on Arvinas’ website, with replays available for 30 days. Arvinas is advancing therapies using its PROTAC® platform to address life-threatening diseases, including prostate and breast cancers.
Arvinas, a clinical-stage biopharmaceutical company, reported its financial results for Q4 and the full year ended December 31, 2020. The company raised $431.9 million from a public stock offering, closing with $688.5 million in cash and equivalents. Q4 revenues decreased to $2.2 million from $4.9 million year-over-year, while total revenue for 2020 was $21.8 million, down from $43.0 million in 2019. A net loss expanded to $41.5 million in Q4, totaling $119.3 million for the year. However, the company noted significant clinical progress in its ARV-471 and ARV-110 programs.
Arvinas, a clinical-stage biopharmaceutical company, announced that its President and CEO, John Houston, and Chief Scientific Officer, Ian Taylor, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on February 11 at 4:30 p.m. ET. The event will be accessible via a live audio webcast on Arvinas’ website. The company focuses on developing innovative therapies that target disease-causing proteins, with ongoing clinical programs for ARV-110 and ARV-471 aimed at treating advanced forms of prostate and breast cancer respectively.
Arvinas, Inc. (Nasdaq: ARVN) announced the full exercise of the underwriter's option to purchase additional shares in its recent public offering, resulting in a total sale of 6,571,428 shares. This offering has generated approximately $431.9 million in net proceeds. Goldman Sachs & Co. LLC and Piper Sandler & Co. managed the offering, with additional support from Cantor Fitzgerald & Co. and BMO Capital Markets. The press release clarifies this is not an offer to sell or solicit any securities unlawfully.
Arvinas, Inc. (Nasdaq: ARVN) has priced a public offering of 5,714,286 shares of its common stock at $70.00 per share, with an option for underwriters to purchase an additional 857,142 shares. This offering is expected to close around December 18, 2020, subject to standard conditions. The funds raised will support Arvinas' efforts in developing targeted protein degradation therapies through its PROTAC® platform, which focuses on treating severe diseases. Goldman Sachs and Piper Sandler are leading the underwriting process.
Arvinas, Inc. (Nasdaq: ARVN) has announced a public offering of $250 million of its common stock, with an additional $37.5 million option for underwriters. Goldman Sachs & Co. LLC and Piper Sandler & Co. are the joint book-running managers. This offering is part of a planned strategy to support Arvinas’ ongoing clinical programs, including its two key candidates: ARV-110 for prostate cancer and ARV-471 for breast cancer. The offering is subject to market conditions and investor interest.